Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Research & Development (2019 - 2026)

Atea Pharmaceuticals' Research & Development history spans 8 years, with the latest figure at $41.1 million for Q1 2026.

  • Quarterly Research & Development rose 39.04% to $41.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $159.6 million through Mar 2026, up 37.43% year-over-year, with the annual reading at $148.0 million for FY2025, 2.72% up from the prior year.
  • Research & Development came in at $41.1 million for Q1 2026, down from $47.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $57.6 million in Q1 2024 to a low of $4.9 million in Q3 2022.
  • The 5-year median for Research & Development is $29.6 million (2025), against an average of $31.1 million.
  • Year-over-year, Research & Development crashed 88.6% in 2022 and then soared 474.54% in 2023.
  • Atea Pharmaceuticals' Research & Development stood at $27.5 million in 2022, then increased by 27.25% to $35.0 million in 2023, then fell by 26.75% to $25.7 million in 2024, then soared by 86.27% to $47.8 million in 2025, then fell by 13.98% to $41.1 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Research & Development are $41.1 million (Q1 2026), $47.8 million (Q4 2025), and $38.3 million (Q3 2025).